Editor’s be aware: A livestream of the dialog will likely be embedded beneath at 1 p.m. ET.
Every week, week, STAT+ subscribers get entry to unique conversations with biotech, pharma, and well being tech leaders. This week, STAT normal project reporter and affiliate editorial director of occasions Nicholas St. Fleur will likely be joined by Fouad Namouni, president of analysis and improvement at Blueprint Medicines. They are going to be discussing Blueprint’s work in making focused most cancers medicine, the way forward for oncology, and naturally be taking your questions reside.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED
What’s it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, coverage, and life science protection and evaluation.
Our award-winning crew covers information on Wall Road, coverage developments in Washington, early science breakthroughs and medical trial outcomes, and well being care disruption in Silicon Valley and past.
What’s included?
- Day by day reporting and evaluation
- Probably the most complete trade protection from a powerhouse crew of reporters
- Subscriber-only newsletters
- Day by day newsletters to temporary you on crucial trade information of the day
- STAT+ Conversations
- Weekly alternatives to interact with our reporters and main trade specialists in reside video conversations
- Unique trade occasions
- Premium entry to subscriber-only networking occasions across the nation
- One of the best reporters within the trade
- Probably the most trusted and well-connected newsroom within the well being care trade
- And far more
- Unique interviews with trade leaders, profiles, and premium instruments, like our CRISPR Trackr.